CSIMarket
 
Bioxcel Therapeutics Inc   (BTAI)
 

Breaking down fourth quarter of 2022 numbers, the company's experienced

company delivered fourth quarter of 2022 operating loss of $-52.887 million


Published Mar 22 2023
CSIMarket Team / CSIMarket.com


pills_blue_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons Considering the most recent fiscal period BTAI increased a loss per share at $-1.76 per share, relative to the earnings of $-0.86 per share a year ago financial reporting period, In the prior financial reporting period BTAI realized $-1.49 per share.

Revenue surged by 73.723 % from $0.14 million in the preceding financial reporting period, grew loss from $-1.49 per share.


For the most recent fiscal period Bioxcel Therapeutics Inc realized net loss of $-54.810 million, higher than $-28.183 million a year ago.

BTAI announced loss of $-165.76 million and revenue of $0.38 million in the fiscal 12 Months 2022.

Net loss per share has widen to $-5.92 from $-4.05 in the prior fiscal year, while by 0 % from $0.00 million a year ago.

Bioxcel Therapeutics Inc is expected to report next financial earnings on May 08, 2023.



Bioxcel Therapeutics Inc's Asset Turnover

Bioxcel Therapeutics Inc's ROI



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com